European Journal of Cancer
Papers 36524
1 page of 3,653 pages (36.5k results)
#1Fay H. CaffertyH-Index: 11
#2Jeffrey D. White (Beatson West of Scotland Cancer Centre)H-Index: 27
Last.Robert Huddart (The Royal Marsden NHS Foundation Trust)H-Index: 64
view all 6 authors...
Abstract Background Up to 50% of men with poor prognosis, non-seminoma germ cell tumours (GCTs) die with standard BEP (bleomycin, etoposide and cisplatin) chemotherapy. An intensive regimen, CBOP/BEP (carboplatin, bleomycin, vincristine and cisplatin/BEP), met response targets in a randomised, phase II trial (74% complete response or partial response marker negative, 90% confidence interval (CI) 61%–85%). Aim To assess long-term outcomes and late toxicity associated with CBOP/BEP. Methods Patien...
#1Enriqueta Felip (Hebron University)H-Index: 60
#2Andrea Ardizzoni (UNIBO: University of Bologna)H-Index: 48
Last.Luis Paz-AresH-Index: 55
view all 21 authors...
Abstract Background CheckMate 171 (NCT02409368) is an open-label, multicentre, phase 2 trial of nivolumab in previously treated advanced squamous non-small cell lung cancer (NSCLC), conducted as part of a post-approval commitment to the European Medicines Agency (EMA). We report outcomes from this trial. Methods Patients with Eastern Cooperative Oncology Group performance status (ECOG PS) 0–2 and disease progression during/after ≥1 systemic treatment (≥1 being platinum-based chemotherapy) for ad...
#1Eric Van Cutsem (Katholieke Universiteit Leuven)H-Index: 122
#2Kei MuroH-Index: 45
Last.Zev A. Wainberg (UCLA: University of California, Los Angeles)H-Index: 30
view all 15 authors...
Abstract Background The RAINBOW trial showed that second-line ramucirumab with paclitaxel prolongs overall survival (OS) and progression-free survival (PFS) compared with placebo plus paclitaxel for treatment of advanced gastric/gastroesophageal junction cancer. Plasma samples were collected from patients during the trial and tested to identify predictive and prognostic biomarkers. Patients and methods Circulating factors in plasma samples from mutually exclusive subsets of RAINBOW patients were...
#1Gerd FastnerH-Index: 17
#2Felix SedlmayerH-Index: 25
Last.Michael GnantH-Index: 73
view all 23 authors...
Abstract Purpose To investigate long-term results of patients with hormonal receptor–positive breast cancer treated with breast-conserving surgery (BCS) and consecutive endocrine therapy (ET) with or without whole breast irradiation (WBI). Methods and materials Within the 8 A trial of the Austrian Breast and Colorectal Cancer Study Group, a total of 869 patients received ET after BCS which was randomly followed by WBI (n = 439, group 1) or observation (n = 430, group 2). WBI was applied up to a ...
#1Wen Xu (UQ: University of Queensland)
#2Victoria Atkinson (UQ: University of Queensland)H-Index: 19
Last.Alexander M. Menzies (USYD: University of Sydney)H-Index: 36
view all 3 authors...
Abstract Although immune checkpoint inhibitors have become the standard of care for many tumours, the majority of patients fail to achieve sustained benefit, often owing to the lack of a T-cell inflamed tumour microenvironment (TME). Directly injected intratumoural therapies present a potential strategy to induce T-cell inflammation and convert a ‘cold’ immune-inert TME into a ‘hot’ immune-inflamed TME. Various approaches including chemoablation, oncolytic viral therapy, cytokines and agents tar...
#1Megha Bhardwaj (DKFZ: German Cancer Research Center)H-Index: 3
#2Korbinian Weigl (DKFZ: German Cancer Research Center)H-Index: 5
Last.Hermann Brenner (DKFZ: German Cancer Research Center)H-Index: 119
view all 7 authors...
Abstract Blood-based protein biomarker signatures might be an alternative or supplement to existing methods for early detection of colorectal cancer (CRC) for population-based screening. The objective of this study was to derive a protein biomarker signature for early detection of CRC and its precursor advanced adenoma (AA). In a two-stage design, 270 protein markers were measured by liquid chromatography/multiple reaction monitoring/mass spectrometry in plasma samples of discovery and validatio...
#1Andrew D.J. PearsonH-Index: 64
#2Claudia Rossig (Boston Children's Hospital)H-Index: 21
Last.Lynley V. Marshall (The Royal Marsden NHS Foundation Trust)H-Index: 10
view all 45 authors...
Abstract The third multistakeholder Paediatric Strategy Forum organised by ACCELERATE and the European Medicines Agency focused on immune checkpoint inhibitors for use in combination therapy in children and adolescents. As immune checkpoint inhibitors, both as monotherapy and in combinations have shown impressive success in some adult malignancies and early phase trials in children of single agent checkpoint inhibitors have now been completed, it seemed an appropriate time to consider opportunit...
#1Mario Lamping (Humboldt University of Berlin)
#2Manuela Benary (Humboldt University of Berlin)H-Index: 4
Last.Susen Burock (Humboldt University of Berlin)
view all 20 authors...
Abstract Background Reliable and reproducible interpretation of molecular aberrations constitutes a bottleneck of precision medicine. Evidence-based decision management systems may improve rational therapy recommendations. To cope with an increasing amount of complex molecular data in the clinical care of patients with cancer, we established a workflow for the interpretation of molecular analyses. Methods A specialized physician screened results from molecular analyses for potential biomarkers, ...
#1Julia K. Winkler (Heidelberg University)H-Index: 4
#2Katharina Sies (Heidelberg University)
Last.Andreas BlumH-Index: 31
view all 15 authors...
Abstract Background Deep learning convolutional neural networks (CNNs) show great potential for melanoma diagnosis. Melanoma thickness at diagnosis among others depends on melanoma localisation and subtype (e.g. advanced thickness in acrolentiginous or nodular melanomas). The question whether CNN may counterbalance physicians’ diagnostic difficulties in these melanomas has not been addressed. We aimed to investigate the diagnostic performance of a CNN with approval for the European market across...
Top fields of study
Breast cancer